People who have an inflammatory bowel disease like ulcerative colitis often have problems caused by inflammation in other parts of their bodies. One of these is a skin condition called pyoderma ...

Please provide your email address to receive an email when new articles are posted on . Tumor necrosis factor-alpha inhibitors incited partial (53.2%) and complete clearance (40.4%) in patients with ...

When acne debuts as acne fulminans — acne that manifests as an explosive worsening and ulceration of skin lesions and can be associated with systemic symptoms — heritability is a likely culprit. Dawn ...

Pyoderma gangrenosum (PG) is a rare, ulcerative, cutaneous condition that affects approximately three to 10 individuals per million population each year. 1 Although the condition may affect ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Ulcerative pyoderma gangrenosum is a rare disease with ...

Vilobelimab is a first-in-class anti-human complement factor C5a monoclonal antibody. The Food and Drug Administration (FDA) has granted Fast Track designation to vilobelimab for the treatment of ...

NEW CASTLE, Del.--(BUSINESS WIRE)--In honor of August being International Autoinflammatory Awareness Month, BioTek reMEDys, a multi-site national integrated infusion therapy provider focused on ...

In a recently published systematic review, researchers determined that VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome typically presents in men, with atypical morphology and ...

Specialty pharmacy and drug infusion company BioTek reMEDys, in honor of August being International Autoinflammatory Awareness Month, is calling for “enhanced education and awareness” around these ...

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...

Multi-national, randomized, controlled adaptive Phase III design for vilobelimab in ulcerative pyoderma gangrenosum (PG) Trial size to be adapted upon interim analysis with planned total patient ...